natgillin/translations-raw huggingface dataset:
The proportion of subjects who permanently discontinued treatment due to adverse reactions was 0.2% (5/2,044) and 4.8% (99/2,044) of subjects had ribavirin dose reductions due to adverse reactions. 
Zaradi neželenih učinkov je zdravljenje trajno prekinilo 0,2 % preiskovancev (5/2.044) in 4,8 % (99/2.044) preiskovancem so zaradi neželenih učinkov zmanjšali odmerek ribavirina.
Co-administration may result in increased risk for adverse events. 
Sočasna uporaba lahko povzroči povečano tveganje za pojav neželenih učinkov.
Because of the potential for adverse reactions from the medicinal product in breastfed infants, a decision must be made whether to discontinue breast-feeding or discontinue treatment with Viekirax, taking into account the importance of the therapy to the mother. 
Ker ima zdravilo lahko neželene učinke na dojenčke, se je treba odločiti, ali naj ženska prekine dojenje ali zdravljenje z zdravilom Viekirax, pri čemer je treba upoštevati pomen zdravljenja za mater.
Tell your doctor or pharmacist before taking Viekirax, if you are taking any of the medicines in the table below. 
Obvestite svojega zdravnika ali farmacevta preden boste začeli jemati zdravilo Viekirax, če jemljete katero koli od zdravil v spodnji preglednici.
Ritonavir is an in vitro inhibitor of OCT1, but the clinical relevance is unknown. 
Ritonavir in vitro zavira OCT1, a klinični pomen tega ni znan.
The combination carries an increased risk for hyperbilirubinemia (including ocular icterus), in particular when ribavirin is part of the hepatitis C regimen. 
Kombinacijo spremlja večje tveganje za hiperbilirubinemijo (vključno z očesnim ikterusom), še zlasti, če shema za hepatitis C vključuje ribavirin.
HIV co-infected patients without suppressive antiretroviral therapy should not be treated with Viekirax. 
Bolnikov, sočasno okuženih s HIV in brez supresivnega protiretrovirusnega zdravljenja, se ne sme zdraviti z zdravilom Viekirax.
If more than 12 hours have passed since Viekirax is usually taken, the missed dose should NOT be taken and the patient should take the next dose per the usual dosing schedule. 
Če je od časa, ko po navadi vzame zdravilo Viekirax, minilo že več kot 12 ur, NE SME vzeti izpuščenega odmerka, temveč mora vzeti naslednji odmerek po običajnem urniku jemanja.
PHOSPHODIESTERASE-(PDE-5) INHIBITORS Sildenafil (when used for treatment of pulmonary hypertension) 
ZAVIRALCI FOSFODIESTERAZE TIPA 5 (PDE-5) sildenafil (ko je uporabljen za zdravljenje pljučne hipertenzije)
The dose of ribavirin was left to the discretion of the investigator, with most subjects receiving 600 to 800 mg per day as a starting dose, and most subjects also receiving 600 to 800 mg per day at the end of treatment. 
Odmerek ribavirina je bil prepuščen raziskovalčevi presoji; večina bolnikov je kot začetni odmerek prejemala od 600 do 800 mg na dan in večina bolnikov je tudi na koncu zdravljenja prejemala od 600 do 800 mg na dan.
To maximise absorption, Viekirax tablets should be taken with food, without regard to fat and calorie content (see section 5.2). 
Da bi bila absorpcija čim večja, je treba tablete zdravila Viekirax vzeti s hrano, ne glede na vsebnost maščob in kalorij (glejte poglavje 5.2).
Treatment outcome 
Izid zdravljenja
There are very limited data from the use of Viekirax in pregnant women. 
Podatki o uporabi zdravila Viekirax pri nosečnicah so zelo omejeni.
Paritaprevir is an inhibitor of HCV NS3/4A protease which is necessary for the proteolytic cleavage of the HCV encoded polyprotein (into mature forms of the NS3, NS4A, NS4B, NS5A, and NS5B proteins) and is essential for viral replication. 
Paritaprevir je zaviralec proteaze NS3/4A HCV, ki je potrebna za proteolitično cepitev HCV-kodiranega poliproteina (v zrele oblike proteinov NS3, NS4A, NS4B, NS5A in NS5B) in je nujna za replikacijo virusov.
Avoid concomitant use of tacrolimus or sirolimus with Viekirax and dasabuvir unless the benefits outweigh the risks. 
Izogibajte se sočasni uporabi takrolimusa ali sirolimusa z zdravilom Viekirax in dasabuvirjem, razen kadar koristi uporabe prevladajo nad tveganji.
• Check for side effects of Viekirax or other antiviral medicines your doctor has prescribed for you to use with Viekirax (such as “dasabuvir” and “ribavirin”). 
• preveri neželene učinke zdravila Viekirax ali drugih protivirusnih zdravil, ki vam jih je predpisal za uporabo skupaj z zdravilom Viekirax (kot sta “dasabuvir” in “ribavirin”).
• colchicine in patients with renal or hepatic impairment 
• kolhicin pri bolnikih z okvarami ledvic ali jeter
In Part 1b, SVR12 was achieved by 22/22 (100%) subjects (95% CI: 85.1%, 100%). 
V delu 1b je bil SVR12 dosežen pri 22/22 (100 %) preiskovancih (95 % CI: 85,1 %, 100 %).
However, no dose-adjustment based on gender is warranted. 
Vseeno pa prilagajanje odmerkov glede na spol ni potrebno.
For specific dosage instructions for dasabuvir and ribavirin, including dose modification, refer to the respective Summaries of Product Characteristics. 
Za specifična navodila o odmerjanju dasabuvirja in ribavirina, vključno s prilagajanjem odmerka, glejte ustrezna povzetka glavnih značilnosti zdravila.
D168Y V36Ac, V36Mc, F43Lc, D168H, E357Kc NS5A M28T M28Ve Q30Re Y93H H58D, H58P, Y93N NS5B A553T S556G C316Y, M414T, G554S, S556R, G558R, D559G, D559N, Y561H a. Observed in at least 2 subjects of the same subtype. 
D168Y V36Ac, V36Mc, F43Lc, D168H, E357Kc NS5A M28T M28Ve Q30Re Y93H H58D, H58P, Y93N NS5B A553T S556G C316Y, M414T, G554S, S556R, G558R, D559G, D559N, Y561H a. Opažene pri vsaj 2 preiskovancih istega podtipa.
Therefore, Viekirax with or without dasabuvir is not expected to affect medicinal products which are primarily excreted by the renal route via these transporters (see section 5.2). 
Zato ni pričakovati, da bi zdravilo Viekirax z dasabuvirjem ali brez njega vplivalo na zdravila, ki se v prvi vrsti izločajo skozi ledvice preko teh prenašalcev (glejte poglavje 5.2).
Ombitasvir + paritaprevir + ritonavir* for 12 weeks Treatment-naïve 
Ombitasvir + paritaprevir + ritonavir* 12 tednov Še nezdravljeni
The safety and efficacy of Viekirax in children less than 18 years of age have not been established. 
Varnost in učinkovitost zdravila Viekirax ni ugotovljena pri otrocih, mlajših od 18 let.
Ritonavir was greater than 99% bound to human plasma proteins. 
Ritonavir je bil več kot 99 % vezan na beljakovine v človeški plazmi.
Paritaprevir is metabolised predominantly by CYP3A4 and to a lesser extent CYP3A5. 
Paritaprevir se pretežno presnovi s CYP3A4 in v manjši meri s CYP3A5.
The effect on rilpivirine exposures was similar to that observed when rilpivirine was administered in the morning with food with Viekirax + dasabuvir (shown in the table above). 
Vpliv na izpostavljenost rilpivirinu je bil podoben, kot so ga opažali, če je bil rilpivirin uporabljen zjutraj s hrano z zdravilom Viekirax + dasabuvir (prikazano v zgornji preglednici).
The interactions between pitavastatin and fluvastatin and Viekirax have not been investigated. 
Pitavastatin in fluvastatin Medsebojna delovanja med pitavastatinom in fluvastatinom ter zdravilom Viekirax niso raziskana.
− Feel sick (nauseous), are sick (vomit) or lose your appetite 
− občutite slabost (siljenje na bruhanje), bruhate ali izgubite apetit;
As the incidence of such elevations was 26% among women taking a concomitant ethinyloestradiol-containing medicinal product, such medicinal products are contraindicated with Viekirax with or without dasabuvir. 
Ker je bila incidenca takšnih zvišanj med ženskami, ki so sočasno jemale zdravila z etinilestradiolom, 26 %, so takšna zdravila kontraindicirana med uporabo zdravila Viekirax z dasabuvirjem ali brez njega.
Viekirax should be used in combination with other medicinal products for the treatment of HCV (see Table 1). 
Zdravilo Viekirax je treba uporabljati v kombinaciji z drugimi zdravili za zdravljenje HCV (glejte preglednico 1).
Not studied: 
Ni raziskan:
If you accidentally take more than the recommended dose, you should contact your doctor or go to the nearest hospital straight away. 
Če ste vzeli večji odmerek zdravila Viekirax, kot bi smeli Če ste pomotoma vzeli večji odmerek od priporočenega, takoj obvestite svojega zdravnika ali pojdite v najbližjo bolnišnico.
In contrast, the rate of ALT elevations in subjects using other types of oestrogens as typically used in hormonal replacement therapy (i.e., oral and topical oestradiol and conjugated oestrogens) was similar to the rate observed in subjects who were not using oestrogen-containing products (approximately 1% in each group). 
V nasprotju s tem so bila zvišanja ALT pri tistih, ki so uporabljale druge vrste estrogenov, kakršni se običajno uporabljajo pri hormonskem nadomestnem zdravljenju (tj. peroralni in lokalni estradiol in konjugirani estrogeni), podobna deležu, opaženem med neuporabnicami zdravil z estrogenom (približno 1 % v vsaki skupini).
Ombitasvir was approximately 99.9% bound to human plasma proteins. 
Ombitasvir je bil približno 99,9 % vezan na beljakovine v človeški plazmi.
The long-term clinical impact of the emergence or persistence of virus containing Viekirax- and dasabuvir-resistance-associated substitutions on future treatment is unknown. 
Dolgoročni klinični vpliv pojava oziroma trajnosti virusov s substitucijami, povezanimi z odpornostjo proti zdravilom Viekirax in dasabuvirju, na zdravljenje, v prihodnje ni znan.
Three interrupted Viekirax and dasabuvir for one to seven days, including one on ethinyloestradiol. 
Tri osebe so jemanje zdravila Viekirax in dasabuvirja prekinile za obdobje od enega do sedmih dni; ena od njih je dobivala etinilestradiol.
Viekirax safety and efficacy have been established in combination with dasabuvir and/or ribavirin. 
Varnost in učinkovitost zdravila Viekirax sta bili ugotovljeni v kombinaciji z dasabuvirjem in/ali ribavirinom.
Skin and subcutaneous tissue disorders Very common 
Bolezni kože in podkožja Zelo pogosti srbenje
↑ diltiazem, verapamil 
Pričakovano: ↑ diltiazem, verapamil
Ritonavir is predominantly metabolised by CYP3A and to a lesser extent, by CYP2D6. 
Ritonavir se pretežno presnovi s CYP3A in v manjši meri s CYP2D6.
Low dose ritonavir, which is part of the fixed dose combination Viekirax, may select for PI resistance in HIV co-infected patients without ongoing antiretroviral therapy. 
Majhen odmerek ritonavirja, ki je del fiksne kombinacije odmerkov v zdravilu Viekirax, lahko doseže selekcijo za odpornost na PI pri bolnikih, sočasno okuženih s HIV in brez hkratnega protiretrovirusnega zdravljenja.
There was 1 relapse in the 12week arm and 1 on-treatment virologic failure in the 24-week arm. 
Bil je 1primer recidiva v 12-tedenski skupini in 1 primer virusne neodzivnosti na zdravljenje v 24-tedenski skupini.
In mice, an increased incidence of open eye lid was present in foetuses of dams administered ombitasvir; however, the relationship to treatment with ombitasvir is uncertain. 
Pri miših so ugotovili večjo incidenco odprtih očesnih vek pri plodovih samic, ki so dobivale ombitasvir, vendar povezanost z zdravljenjem z ombitasvirjem ni gotova.
Ombitasvir, paritaprevir and ritonavir are highly bound to plasma proteins. 
Ombitasvir, paritaprevir in ritonavir so v zelo veliki meri vezani na beljakovine v plazmi.
Co-administration of Viekirax with everolimus is not recommended because of a significant increase in everolimus exposures which cannot be properly dose adjusted with available dose strengths (see section 4.4). 
Sočasna uporaba zdravila Viekirax z everolimusom ni priporočljiva zaradi izrazitega povečanja izpostavljenosti everolimusu, katerega odmerek ne more biti ustrezno prilagojen z jakostmi odmerkov, ki so na voljo (glejte poglavje 4.4).
In Phase 3 clinical trials, 1075 subjects (including 181 with compensated cirrhosis) with genotype 1 HCV infection received the recommended regimen (see section 4.2). 
Kumulativna analiza učinkovitosti V kliničnih preskušanjih 3. faze je 1075 preiskovancev (vključno s 181 s kompenzirano cirozo), okuženih s HCV genotipa 1, prejelo priporočeno shemo (glejte poglavje 4.2).
Substitution L28V in HCV NS5A reduced the susceptibility to ombitasvir by 21-fold. 
Substitucija L28V v genu NS5A HCV je zmanjšala občutljivost za ombitasvir za 21-krat.
Ombitasvir Ombitasvir is an inhibitor of HCV NS5A which is essential for viral replication. 
Ombitasvir je zaviralec beljakovine NS5A HCV, ki je nujna za replikacijo virusov.
Examples of contraindicated enzyme inducers are provided in section 4.3. 
Primeri kontraindiciranih induktorjev encimov so navedeni v poglavju 4.3.
Viekirax with dasabuvir is expected to increase the exposure to rosuvastatin more than 3-fold. 
Pričakovati je, da zdravilo Viekirax z dasabuvirjem poveča izpostavljenost rosuvastatinu za več kot 3-krat.
Ombitasvir and its major inactive human metabolites (M29, M36) were not genotoxic in a battery of in vitro or in vivo assays, including bacterial mutagenicity, chromosome aberration using human peripheral blood lymphocytes and in vivo mouse micronucleus assays. 
Ombitasvir in njegova glavna neaktivna presnovka pri človeku (M29, M36) niso bili genotoksični v skupini preizkusov in vitro ali in vivo, vključno s preizkusom mutagenosti pri bakterijah, preizkusom kromosomskih aberacij na človeških limfocitih iz periferne krvi in v mikrojedrnem preizkusu in vivo pri miših.
Co-administration of efavirenz (enzyme inducer) based regimens with paritaprevir /ritonavir + dasabuvir resulted in ALT elevations and therefore, early discontinuation of the study. 
Sočasna uporaba shem na podlagi efavirenza (ki je induktor encima) in kombinacije paritaprevir/ritonavir + dasabuvir je povzročila zvišanje ALT in zaradi tega zgodnje prenehanje študije.
What Viekirax looks like and contents of the pack 
Izgled zdravila Viekirax in vsebina pakiranja
Extreme caution must be taken to avoid pregnancy in female patients and female partners of male patients when Viekirax is taken in combination with ribavirin, see section 4.6 and refer to the Summary of Product Characteristics for ribavirin for additional information. 
Da bi se izognili nosečnosti pri bolnicah in partnericah bolnikov, kadar se zdravilo Viekirax jemlje v kombinaciji z ribavirinom, je potrebna skrajna previdnost, glejte poglavje 4.6 in za dodatne informacije povzetek glavnih značilnosti zdravila za ribavirin.
If statin treatment is required during the treatment period, a switch to dose reduced pravastatin or rosuvastatin is possible. 
Če je med obdobjem zdravljenja potrebno zdravljenje s statinom, je treba preiti na zmanjšani odmerek pravastatina ali rosuvastatina, če je mogoče.
Viekirax tablets are pink, oblong film-coated tablets of dimmensions 18.8 mm x 10.0 mm, marked with ‘AV1'. 
Tablete zdravila Viekirax so rožnate, podolgovate, filmsko obložene tablete velikosti 18,8 mm x 10,0 mm, z oznako "AV1".
Extra precautions are needed if Viekirax is taken together with ribavirin. 
Posebna previdnost je potrebna, če se zdravilo Viekirax jemlje skupaj z ribavirinom.
NNRTIs other than rilpivirine (efavirenz, etravirine and nevirapine) are contraindicated (see section 4.3). 
Drugi NNRTI, razen rilpivirina (efavirenz, etravirin in nevirapin), so kontraindicirani (glejte poglavje 4.3).
The marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP. 
podrobno opisane v sprejetem RMP, predloženem v modulu 1.8.2 dovoljenja za promet z zdravilom, in vseh nadaljnjih sprejetih posodobitvah RMP.
Concerning genotypespecific virological and clinical activity, see section 5.1. 
Za virusno in klinično aktivnost, specifično za genotip, glejte poglavje 5.1.
HCV ANTIVIRALS Sofosbuvir 
PROTIVIRUSNA ZDRAVILA PROTI HCV sofosbuvir
For dosing recommendations with calcineurin inhibitors see section 4.5. 
Za priporočila o odmerjanju z zaviralci kalcinevrina glejte poglavje 4.5.
HIV protease inhibitors other than atazanavir and darunavir (e.g., indinavir, saquinavir, tipranavir, lopinavir/ritonavir) are contraindicated (see section 4.3). 
Drugi zaviralci proteaze HIV, razen atazanavirja in darunavirja (npr. indinavir, sakvinavir, tipranavir, lopinavir/ritonavir) so kontraindicirani (glejte poglavje 4.3).
ANTIFUNGALS Ketoconazole 400 mg once daily 
ANTIMIKOTIKI ketokonazol 400 mg enkrat na dan
Patients should be informed that fatigue has been reported during treatment with Viekirax in combination with dasabuvir and ribavirin (see section 4.8). 
Bolnikom je treba povedati, da je bila med zdravljenjem z zdravilom Viekirax v kombinaciji z dasabuvirjem in ribavirinom opisana utrujenost (glejte poglavje 4.8).
Based on population pharmacokinetic analysis of data from Phase 3 clinical studies, female subjects would have approximately 55% higher, 100% higher and 15% higher ombitasvir, paritaprevir and ritonavir exposures than male subjects. 
Na osnovi analize populacijske farmakokinetike iz kliničnih študij 3. faze bi imele preiskovanke približno 55 % večjo izpostavljenost ombitasvirju, 100 % večjo izpostavljenost paritaprevirju in 15 % večjo izpostavljenost ritonavirju kot moški preiskovanci.
To maximise absorption, Viekirax should be taken with food without regard to fat or calorie content. 
Da bi bila absorpcija čim večja, je treba zdravilo Viekirax vzeti s hrano, ne glede na vsebnost maščob in kalorij.
GASTROINTESTINAL PRODUCTS (PROPULSIVE) Cisapride 
ZDRAVILA Z DELOVANJEM V PREBAVILIH (PROPULZIVI) cisaprid
Potent inhibitors of P-gp, BCRP, OATP1B1 and/or OATP1B3 have the potential to increase the exposure to paritaprevir. 
Močni zaviralci P-gp, BCRP, OATP1B1 in/ali OATP1B3 lahko povečajo izpostavljenost paritaprevirju.
Coadministration with ethinyloestradiol may increase the risk of ALT elevations (see sections 4.3 and 4.4). 
Sočasna uporaba z etinilestradiolom lahko poveča tveganje za zvišanje ALT (glejte poglavji 4.3 in 4.4).
Viekirax with or without dasabuvir was also evaluated without ribavirin in 18 GT1a- and GT4-infected patients; no adverse events of anaemia were seen in these subjects. 
Zdravilo Viekirax z ali brez dasabuvirja je bil ovrednoten tudi brez ribavirina pri 18 bolnikih, okuženih z GT1a in GT4; pri teh preiskovancih niso opazili nobenih neželenih učinkov anemije.
All treatment-emergent variants in NS5A remained detectable at post-treatment Week 48. 
Vse med zdravljenjem nastale variante gena NS5A so ostale zaznavne 48. teden po zdravljenju.
Viekirax with or without dasabuvir was administered as multiple doses in all the drug interaction studies except the drug interaction studies with carbamazepine, gemfibrozil, ketoconazole, and sulfamethoxazole/trimethoprim.. 
Zdravilo Viekirax z dasabuvirjem ali brez njega so uporabljali v večkratnih odmerkih v vseh študijah medsebojnega delovanja zdravil, razen v študijah medsebojnega delovanja s karbamazepinom, gemfibrozilom, ketokonazolom in kombinacijo sulfametoksazol/trimetoprim.
Drug interactions need to be carefully taken into account in the setting of HIV co-infection (for details see section 4.5, Table 2). 
Pri bolnikih, ki so sočasno okuženi s HIV, je treba skrbno upoštevati medsebojna delovanja zdravil (za podrobnosti glejte poglavje 4.5, preglednico 2):
It is not known whether the active substances in Viekirax (ombitasvir, paritaprevir and ritonavir) pass into breast milk. 
Ni znano, ali učinkovine v zdravilu Viekirax (ombitasvir, paritaprevir in ritonavir) prehajajo v materino mleko.
− Tablet film-coating: poly(vinyl alcohol) (E 1203), macrogol (3350), talc (E 553b), titanium dioxide (E 171) and red iron oxide (E 172). 
− Filmska obloga tablete: polivinilalkohol (E 1203), makrogol 3350, smukec (E 553b), titanov dioksid (E 171), rdeči železov oksid (E 172).
The combination of atazanavir and Viekirax + dasabuvir increase bilirubin levels, in particular when ribavirin is part of the hepatitis C regimen (see sections 4.4 and 4.8). 
Kombinacija atazanavirja in zdravila Viekirax + dasabuvirja zviša ravni bilirubina, zlasti kadar je ribavirin del sheme zdravljenja okužbe z virusom hepatitisa C (glejte poglavji 4.4 in 4.8).
The effect on Cmax and AUC of DAAs and lopinavir was similar to that observed when lopinavir/ritonavir 400/100 mg twice daily was administered with Viekirax with or without dasabuvir. 
Vpliv na Cmax in AUC DAA in lopinavirja je bil podoben, kot ko sta bila lopinavir/ritonavir 400 mg/100 mg dvakrat na dan uporabljena skupaj z zdravilom Viekirax, z dasabuvirjem ali brez njega.
No dose adjustment of gemfibrozil is necessary. 
Prilagoditev odmerka gemfibrozila ni potrebna.
Although ALT elevations associated with Viekirax and dasabuvir have been asymptomatic, patients should be instructed to watch for early warning signs of liver inflammation, such as fatigue, weakness, lack of appetite, nausea and vomiting, as well as later signs such as jaundice and discoloured faeces, and to consult a doctor without delay if such symptoms occur. 
Čeprav so bila z zdravilom Viekirax in dasabuvirjem povezana zvišanja ALT asimptomatska, je treba bolnikom naročiti, da morajo biti pozorni na zgodnje opozorilne znake vnetja jeter, npr. na utrujenost, šibkost, pomanjkanje apetita, navzeo in bruhanje, pa tudi na poznejše znake, npr. zlatenico, spremembo barve blata, in da se morajo v primeru pojava simptomov brez odlašanja posvetovati z zdravnikom.
Hydrocodone (as given in a fixed-dose hydrocodone/ paracetamol) 
Hidrokodon (kot fiksni odmerek kombinacije hidrokodon/par acetamol)
• efavirenz, nevirapine, etravirine 
• efavirenz, nevirapin
Unchanged ombitasvir was the predominant component observed in the milk of lactating rats, without effect on nursing pups. 
Nespremenjeni ombitasvir je bil glavna snov v mleku doječih podgan, brez vpliva na dojene mladiče.
In the greater than 500 genotype 1a baseline samples in this analysis, the most frequently observed resistance-associated variants were M28V (7.4%) in NS5A and S556G (2.9%) in NS5B. 
V več kot 500 izhodiščnih vzorcih genotipa 1a v tej analizi sta bili najpogosteje opaženi z odpornostjo povezani varianti M28V (7,4 %) v NS5A in S556G (2,9 %) v NS5B.
HIV ANTIVIRALS: NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS Rilpivirine2 
PROTIVIRUSNA ZDRAVILA PROTI HIV: NENUKLEOZIDNI ZAVIRALCI REVERZNE TRANSKRIPTAZE rilpivirin2
↔ dasabuvir sirolimus is used together with Viekirax + dasabuvir, administer sirolimus 0.2 mg twice a week (every 3 or 4 days on the same two days each week). 
Če je sirolimus uporabljen skupaj z zdravilom Viekirax in dasabuvirjem, dajte sirolimus 0,2 mg dvakrat na teden (vsake 3 ali 4 dni na enaka dva dni vsak teden).
Atazanavir can be used in combination with Viekirax and dasabuvir, if administered at the same time. 
Atazanavir se lahko uporablja v kombinaciji z zdravilom Viekirax in dasabuvirjem, če se dajejo ob istem času.
How long to take Viekirax for 
Kako dolgo jemati zdravilo Viekirax
Concomitant use of Viekirax and glucocorticoids, particularly long-term use, should only be initiated if the potential benefit of treatment outweighs the risk of systemic corticosteroid effects (see section 4.5). 
Sočasno uporabo zdravila Viekirax in glukokortikoidov, zlasti v primeru dolgoročne uporabe, se sme začeti le, če možna korist zdravljenja odtehta tveganja za sistemske učinke kortikosteroidov (glejte poglavje 4.5).
Table 20. 
Preglednica 20.
Accumulation is minimal for ombitasvir and approximately 1.5- to 2-fold for ritonavir and paritaprevir. 
Kopičenje ombitasvirja in dasabuvirja je minimalno, kopičenje ritonavirja in paritaprevirja pa približno 1,5- do 2-kratno.
Genotype 1a, with compensated cirrhosis 
Genotip 1a, s kompenzirano cirozo
Purpose of the medicine alfuzosin for an enlarged prostate amiodarone, disopyramide, dronedarone used to correct irregular heartbeats astemizole, terfenadine for allergy symptoms. 
Namen uporabe zdravila alfuzosin pri povečani prostati amiodaron, dizopiramid, dronedaron za uravnavanje nerednega srčnega utripa astemizol, terfenadin pri simptomih alergije.
Substitutions R155C, A156T/V, and D168H/V in HCV NS3 reduced susceptibility to paritaprevir by 40- to 323-fold. 
Substitucije R155C, A156T/V in D168H/V v HCV NS3 so zmanjšale občutljivost za paritaprevir za 40- do 323-krat.